Skye Bioscience, Inc. Common Stock (SKYE) is a publicly traded Healthcare sector company. As of August 14, 2026, SKYE trades at $0.53 with a market cap of $19.29M and a P/E ratio of -0.38. SKYE moved -1.85% today. Year to date, SKYE is -38.40%; over the trailing twelve months it is -82.77%. Its 52-week range spans $0.28 to $5.75. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces SKYE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest SKYE news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $0.53 |
| Market Cap | $19.29M |
| P/E Ratio | -0.38 |
| EPS | $-1.41 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.75 |
| 52-Week Low | $0.28 |
| Volume | 610 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-55.92M |
| Gross Margin | 0.00% |
3 analysts cover SKYE: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.